Search | Clinical Trials Finder

Conditions: HIV Antiretroviral Therapy (ART) Adherence, Health Behavior
Interventions: LifeWindows Intervention Sessions, Control; Behavioral · Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Farmington, Connecticut • Hartford, Connecticut • New Haven, Connecticut + 1 more

Conditions: HIV Infections
Interventions: Atazanavir, Didanosine, Efavirenz, Emtricitabine/Tenofovir disoproxil fumarate, Lamivudine, Lopinavir/Ritonavir, Nevirapine, Stavudine, Tenofovir disoproxil fumarate, Zidovudine/Lamivudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 3,526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV-1 Infection
Interventions: elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 23
States / cities: Birmingham, Alabama • San Diego, California • Torrance, California + 17 more

Conditions: HIV Infections
Interventions: a1DC + inactivated whole autologous HIV, a1DC + conserved HIV peptides, a1DC + no antigen, pgDC + inactivated whole autologous HIV, pgDC + conserved HIV peptides, pgDC + no antigen; Biological
Lead sponsor: Sharon Riddler; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Columbus, Ohio • Pittsburgh, Pennsylvania

Conditions: Eating Disorders, Anorexia Nervosa, Bulimia Nervosa, Atypical Anorexia Nervosa, Purging (Eating Disorders), Other Specified Feeding or Eating Disorder, Social Anxiety Disorder, Generalized Anxiety Disorder (GAD)
Interventions: Educational, Interactive; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Torrance, California + 8 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1-infection, Metabolic Syndrome, Cardiovascular Diseases, Weight Gain, Renal Function Abnormal, Hyperglycemia
Interventions: Tenofovir Alafenamide; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Syphilis
Interventions: Cepheid GeneXpert HIV-1 Qual POC HIV VL test, DPP HIV-Syphilis test system, OraQuick; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: blood draw; Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 8 more

Conditions: HIV Infections, Pregnancy
Interventions: Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: VH3810109, Fostemsavir (FTR), SOC INSTI-based ART; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Bakersfield, California • San Diego, California • Ft. Pierce, Florida + 9 more

Conditions: HIV Infections
Interventions: Tucaresol; Drug
Lead sponsor: Aaron Diamond AIDS Research Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Interventions: Art Therapy, Interview, Survey Administration; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 10 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: Psychological Trauma, PTSD
Interventions: Accelerated Resolution Therapy (ART), Waitlist; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Atazanavir (immediate switch), Atazanavir (Week 24 switch); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 19
States / cities: Phoenix, Arizona • West Hollywood, California • Washington D.C., District of Columbia + 16 more

Conditions: HIV/AIDS
Interventions: Treatment Interruption Arm; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HAART Non-Adherence, HIV, HIV Infections
Interventions: Cell Phone Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 15 Years to 24 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 2 more

Conditions: HIV Infections, Human Immunodeficiency Virus
Interventions: SP01A; Drug
Lead sponsor: Samaritan Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 5
States / cities: Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 10
States / cities: Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more

Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus, Human Immunodeficiency Viruses
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infection
Interventions: HPV vaccine for strains -6, -11, -16, and -18; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 23 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: HIV
Interventions: Heart to Heart2 (HTH2); Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Improving Treatment Adherence in HIV-Infected Individuals

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Early ART to Limit Infection and Establishment of Reservoir

Comparison of Dendritic Cell-Based Therapeutic Vaccine Strategies for HIV Functional Cure

Targeting Social Function in Anxiety and Eating Disorders

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Immunologic Control of Drug Resistant HIV

Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen

Ending the HIV Epidemic Through Point-of-Care Technologies (EHPOC)

PK of Once Daily ART Containing Tenofovir and Atazanavir/Ritonavir

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women

HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)

A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

Virtual Art Therapy Assisted Re-Integration to Improve Biopsychosocial Outcomes in Adolescent and Young Adult Cancer Survivors, AVATARS Trial

Accelerated Resolution Therapy (ART) for Psychological Trauma

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

SCOPE Analytic Treatment Interruption Protocol

Cell Phone Reminders Intervention

SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Using MOST to Optimize an HIV Care Continuum Intervention for Vulnerable Populations